ONL Therapeutics

Quick facts

Phase 2 pipeline

• Avacincaptad Pegol intravitreal solution · Ophthalmology
  Avacincaptad pegol is an anti-vascular endothelial growth factor (VEGF) agent.
• ONL1204 Opthalmic solution

Phase 1 pipeline

• ONL1204

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• ONL Therapeutics portfolio CI brief
• ONL Therapeutics pipeline updates RSS